Didn’t register for ACR this year? These top tweets are excellent standalone summaries of some of the most talked about sessions.
Didn’t register for ACR this year? These top tweets are excellent standalone summaries of some of the most talked about sessions.
Clinical Year in Review | Presented by Dr. Carol Langford at #ACR22
— Mithu Maheswaranathan, MD (@MithuRheum) November 13, 2022
🌟 Review the Most Important Clinical Research Studies in the Past Year in #Rheumatology! 💫 pic.twitter.com/Ao11xX1bYt
✅ NEW (draft) CRITERIA for the #ANTIPHOSPHOLIPID syndrome have been presented by Erkan et al. during #ACR22. Here is my summary slide ⬇️#Rheumtwitter #MedTwitter pic.twitter.com/XoCNHbqDn2
— Laurent ARNAUD (@Lupusreference) November 14, 2022
Stop MTX and increase folic acid to 5 mg/day for pts who find themselves with an unintentional #pregnancy. –@CuoghiE #ACR22 @rheumnow pic.twitter.com/uChPU6zrwv
— TheDaoIndex (@KDAO2011) November 13, 2022
🆕 #Rheumatology Secrets & Pearls at #ACR22 | By Dr. @JKolfenbach & Dr. John Stone (@MGHrheumatology) 📚
— Mithu Maheswaranathan, MD (@MithuRheum) November 14, 2022
Unique Pearls to Know:
💊 Reducing Steroids; PPI & MMF
🦵 Scleroderma Mimics
🫁 FVC/DLCO Ratio for ILD vs PAH
👁️ Inflammatory Eye Dz
🤰🏽 Changes in Pregnancy: C3/4, UPC, sCr pic.twitter.com/22Pnd7AZzQ
vasculitis mimickers with Dr. Matthew Koster
— Vaneet K Sandhu, MD, RhMSUS (she/her) (@vksandhumd) November 13, 2022
– SAM v FMD can look just like string of beads in same organs as vasculitis
– celiac/mesenteric > in SAM vs renal in FMD
– renal/mesenteric > in PAN
– ao/major branches > in CollVascDz#ACR22 #ACRAmbassador pic.twitter.com/yVUwUkivEo
There's a lot of Scleroderma-like fibrosing skin disorders!#ACR22 @RheumNow #RheumTwitter @rheumarhyme pic.twitter.com/W1AEtfeKZc
— sheila (@RHEUMarampa) November 13, 2022
✨How do you treat Skin disease in #SystemicSclerosis✨
— Ashima Makol MD (@AshimaMakol) November 12, 2022
👇👇👇
1st- MMF/Myfortic (if GI intol) or MTX (get baseline HRCT 1st)
2nd- CYC or Autologous SCT if refractory; ✅Trials
RTX (add on?),TCZ (no effect), JAKi- 🚫data#SclerodermaCommunityHub#ACR22 @ACRheum #ACRambassador pic.twitter.com/BrmQzbYdwu
2022 ACR guide for #vaccinations in RMD pts:
— sheila (@RHEUMarampa) November 12, 2022
💉Influenza:⬆️dose or adjuvant (CR) >=65 & >18<65 on immunosuppressives
💉Pneumococcal: SR for <65 yrs, on immunosuppressives
💉Rec VZV: SR for >18y on immunosupressives
💉HPV: CR for >26y & <45y on meds & no prev vax#ACR22 @rheumnow pic.twitter.com/2DlIqNUBct
How long do we hold meds for live-attenuated #Vaccines? ACR 2022 vax guidelines:
— sheila (@RHEUMarampa) November 12, 2022
💉Pre-vax:
💊csDMARDs – hold time 4 wks
💊bDMARDs -hold time of one dosing interval
💉Post-vax: hold DMARDs for 4 wks#ACR22 @rheumnow @rheumarhyme @doktora_ging pic.twitter.com/MGc422EtIC
#ACR22 #ACR2022
— EnvisionRheumat (@ERheumat) November 12, 2022
12S110. Plenary I
Cancer Screening Recommendations for Patients with Idiopathic Inflammatory Myopathy pic.twitter.com/lei4XstxcO
A #myositis discussion will not be complete without a slide on myositis antibodies – @JuliePaikMD
— sheila (@RHEUMarampa) November 12, 2022
Great review slide for trainees! #ACR22 @Rheumnow #RheumTwitter @rheumarhyme @PhRheumaJr @doktora_ging pic.twitter.com/e6cB344vH8
Not all dry eyes and mouth is due to Sjogren’s syndrome (SS). Think of mimics including diabetes, HCV, HIV, sarcoidosis.
— Dr. Antoni Chan (@synovialjoints) November 11, 2022
Equally, not all parotid enlargement is due to SS. Think of mimics including IgG4, sialodenosis #ReviewCourse @RheumNow #ACR22 pic.twitter.com/zPwRRtdGjT
2022 ACR/EULAR Classification Criteria for GCA was published 2 days ago! In time for the #acr22 & #vasculitis meeting. @DrPeterMerkel @ACRheum https://t.co/M1oaEw8yYS pic.twitter.com/6lBBH0tt1G
— Dr. Geraldine Zamora (@doktora_ging) November 11, 2022
ASAS-EULAR Rec for AxSpA 2022
— Dr. Antoni Chan (@synovialjoints) November 11, 2022
◦ NSAIDs are first line
◦ b/tsDMARDs when ASDAS >2.1
◦ Uveitis/IBD ➤TNFi
◦ Psoriasis ➤IL-17i
◦ Review Dx if Rx failure
◦ Switch if active disease confirmed
◦ Taper bDMARDs if sustained remission
Jose Scher #ReviewCourse @RheumNow #ACR22 pic.twitter.com/8fGwlZWBDS
HCQ tx thresholds study by Prof Garg:
— sheila (@RHEUMarampa) November 13, 2022
🔸HCQ >=500ng/ml: good threshold to detect adherence
🔸HCQ 750-1000ng/ml: effective thresholds to prevent flares
🔸CKD>=2: 4x ⬆️odds of HCQ>1500ng/ml (supraTx! dose adj.)
Interesting data.
Game changing?🧐#ACR22 @RheumNow ABST#0344 #ACRBest pic.twitter.com/GxlucrTeE5
